First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort

被引：1
|
作者：
Yang, J. C-H. [1 ,2 ]
Kobayashi, K. [3 ]
Chewaskulyong, B. [4 ]
Tran, T. V. [5 ]
Biswas, B. [6 ]
Lee, K. H. [7 ]
Feng, P-H. [8 ]
Pham, X. D. [9 ]
Yao, Y. [10 ]
Kuyama, S. [11 ]
Bing, J. Y. Tan Chun [12 ]
Bhise, R. [13 ,14 ]
Ahn, M-J. [15 ]
Sriuranpong, V. [16 ,17 ]
Li, R. K. [18 ]
Monterroso, E. Armenteros [19 ]
Barrett, K. [20 ]
Albayaty, M. [21 ]
Cheng, Y. [22 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan
[2] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan
[3] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan
[4] Chiang Mai Univ, Dept Med, Chiang Mai, Muang, Thailand
[5] Univ Med Ctr, Dept Chemotherapy, Ho Chi Minh City, Vietnam
[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India
[7] Chungbuk Natl Univ, Dept Internal Med, Cheongju, South Korea
[8] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Taipei, Taiwan
[9] HCMC Oncol Hosp, Dept Med Oncol, Ho Chi Minh City, Vietnam
[10] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Oncol, Xian, Peoples R China
[11] Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Japan
[12] Cebu Doctors Univ Hosp, Dept Internal Med, Cebu, Philippines
[13] JN Med Coll, Dept Med Oncol, Belagavi, India
[14] KLES Dr Prabhakar Kore Hosp & MRC, Belagavi, India
[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[16] Chulalongkorn Univ, Fac Med, Div Med Oncol, Bangkok, Thailand
[17] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[18] St Lukes Med Ctr, Inst Canc, Quezon City, Philippines
[19] AstraZeneca, Oncol R&D, Late Stage Dev, Barcelona, Spain
[20] AstraZeneca, Oncol R&D, Late Stage Dev, Biometr, Cambridge, England
[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England
[22] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
630MO
引用
收藏
页码：S1635 / S1636
页数：3
相关论文
共 50 条
  • [41] First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
    Nie, Naifu
    Li, Jianghua
    Zhang, Jian
    Dai, Jie
    Liu, Zhulin
    Ding, Zhenyu
    Wang, Yubo
    Zhu, Mengxiao
    Hu, Chen
    Han, Rui
    Tang, Huan
    Li, Li
    He, Yong
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [42] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    ANNALS OF ONCOLOGY, 2015, 26
  • [43] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [44] Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
    Araki, Taisuke
    Kanda, Shintaro
    Horinouchi, Hidehito
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 547 - 561
  • [45] Resistance mechanisms in EGFR-mutated advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with first-line osimertinib (osi) and monitoring plasma mutational load: Preliminary results of REM study
    Bonanno, L.
    Ferro, A.
    Bao, L. C.
    Marinato, G. M.
    Padovan, A.
    Zulato, E.
    Frega, S.
    Dal Maso, A.
    Pasello, G.
    Indraccolo, S.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2023, 34
  • [46] What is the Optimal First-Line Regimen for EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
    Zhang, W.
    Guo, Z.
    Ye, L.
    Chen, Z.
    Xu, K.
    Liu, X.
    Liu, Y.
    Wang, H.
    Zhao, L.
    Zhao, W.
    He, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S619
  • [47] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [48] OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer
    Tan, D. S. W.
    Amin, N.
    Madondo, M.
    Chapaneri, J.
    Tang, K. H.
    Taylor, R.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S338 - S339
  • [49] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
    Cronin-Fenton, D.
    Dalvi, T.
    Hedgeman, E.
    Norgaard, M.
    Petersen, L.
    Hansen, H.
    Fryzek, J.
    Lawrence, D.
    Walker, J.
    Mellemgaard, A.
    Rasmussen, T.
    Shire, N.
    Rigas, J.
    Potter, D.
    Hamilton-Dutoit, S.
    Sorensen, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085
  • [50] Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
    Bonanno, L.
    Bao, L. C.
    Padovan, A.
    Ferro, A.
    Bianco, A.
    Calvetti, L.
    Pavan, A.
    Ziampiri, S.
    Zulato, E.
    Marinato, G. M.
    Dal Maso, A.
    Frega, S.
    Pasello, G.
    Guarneri, V.
    Indraccolo, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S256 - S256
12345